Serotonin warning for users of SSRIs

Share this article:
The FDA says development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly's Cymbalta (duloxetine HCl) delayed release capsules, Wyeth's Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly's Prozac (fluoxetine capsules and oral solution) and Lilly's Symbyax (olanzapine and fluoxetine HCL capsules).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions